2019
DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial.
Sundar R, Ng A, Zouridis H, Sheng T, Zhang S, Lee M, Padmanabhan N, Ooi W, Qamra A, Nankivell M, Langley R, Allum W, Cunningham D, Grabsch H, Tan P. DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial. Journal Of Clinical Oncology 2019, 37: 43-43. DOI: 10.1200/jco.2019.37.4_suppl.43.Peer-Reviewed Original ResearchDNA methylationCpG sitesMethylation signaturesChemotherapy benefitNeoadjuvant chemotherapyPoor riskGood riskMethylation statusDNA methylation of genesIndependent predictor of survivalDNA methylation signaturesPredictive marker of survivalIllumina GoldenGate platformMethylation of genesCycles of cisplatinCox proportional hazards analysisResectable esophageal carcinomaMarker of survivalPredictive of benefitPredictors of survivalProportional hazards analysisGoldenGate platformSite signatureEpigenetic signaturesSurgery arm
2003
Biologic Predictors of Survival in Node-Negative Gastric Cancer
Kooby D, Suriawinata A, Klimstra D, Brennan M, Karpeh M. Biologic Predictors of Survival in Node-Negative Gastric Cancer. Annals Of Surgery 2003, 237: 828-837. PMID: 12796579, PMCID: PMC1514693, DOI: 10.1097/01.sla.0000072260.77776.39.Peer-Reviewed Original ResearchConceptsPredictors of survivalNode-negative gastric cancerFactors predictive of survivalNeural invasionPredictive of survivalTumor sizeGastric adenocarcinomaPresence of VICurative resectionT stageSerosal invasionVascular invasionFactors associated with poor disease-specific survivalGastric cancerNode-negative gastric adenocarcinomaAbsence of lymph node metastasisDisease-specific survival ratesIndependent predictor of survivalPoor disease-specific survivalMarker of advanced diseasePredictor of poor survivalMedian tumor sizeDisease-specific survivalLymph node metastasisDistal subtotal gastrectomy
1994
p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients.
Zeng Z, Sarkis A, Zhang Z, Klimstra D, Charytonowicz E, Guillem J, Cordon-Cardo C, Cohen A. p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. Journal Of Clinical Oncology 1994, 12: 2043-50. PMID: 7931472, DOI: 10.1200/jco.1994.12.10.2043.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoembryonic AntigenCell NucleusColorectal NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesGenes, p53HumansImmunohistochemistryLymph NodesLymphatic MetastasisMaleMiddle AgedMultivariate AnalysisPrognosisProportional Hazards ModelsTumor Suppressor Protein p53ConceptsColorectal cancer patientsNuclear p53 overexpressionP53 overexpressionCancer patientsPrimary tumorCarcinoembryonic antigenPreoperative serum carcinoembryonic antigenIndependent predictor of survivalP53 nuclear proteinP53-negative groupP53-positive patientsP53 nuclear stainingP53-negative patientsPreoperative CEA levelDisease-specific survivalMedian Follow-UpP53 nuclear overexpressionSerum carcinoembryonic antigenPatients died of colorectal cancerMonoclonal antibody PAbVascular vessel invasionPredictors of survivalP53 gene overexpressionFollow-up dataColorectal mucosal cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply